Poisons board says hypertension drug is safe
SEE ALSO :86 illegal pharmacies shut down"Therefore, there is no strong evidence to warrant the stoppage of use of HCTZ in our local setting," said the board's Chief Executive Officer Fred Siyoi. Siyoi said nevertheless, health care providers are advised to encourage the patients not to stop their medication but to look out for any suspicious lesions on their skin and report to the nearest health facility or health care provider. "In addition, they (health care providers) need to take proper history of patients so that those who may be genetically predisposed to skin cancer because of family history are given alternative medicines," he said. Siyoi said the caution by PPB is a routine post authorization safety update based on epidemiological studies that reported increase in the risk of the Adverse Drug Reactions (ADRs). The board explained that the data of the ADR does not warrant the recall or withdrawal of the products rather calls for restrictions in prescribing and closer monitoring of patients using this group of medicines.
SEE ALSO :Seaside Hospital shut after scrutiny"The recall affected only those products and batches that contained the affected valsartan active ingredient that had been contaminated," he said. Valsartan containing products that were manufactured using the Active Pharmaceutical Ingredients sourced at Zhejiang Huahai Pharmaceuticals, based in Linhai, China. "There are other valsartan products in the market not affected by the recall hence your healthcare provider will guide you appropriately," said the board's boss. He added: "PPB reminds the public that these medicines should only be obtained on prescription from a qualified medical practitioner."
Register to advertise your products & services on our classifieds website Digger.co.ke and enjoy one month subscription free of charge and 3 free ads on the Standard newspaper.